Side-by-side comparison of AI visibility scores, market position, and capabilities
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
Open-source observability leader with $6B valuation; Grafana dashboards plus Loki/Tempo/Mimir stack serving millions of installations as Datadog alternative with community-driven adoption.
Grafana Labs is the company behind Grafana — the world's most widely used open-source observability and data visualization platform — providing the Grafana Cloud managed service, Grafana Enterprise, and a suite of open-source tools including Loki (log aggregation), Tempo (distributed tracing), and Mimir (long-term Prometheus metrics storage). Founded in 2019 by Raj Dutt, Torkel Ödegaard, and Tom Wilkie (the creators of the original Grafana open-source project) in New York, Grafana Labs has raised over $600 million at a $6 billion valuation.\n\nGrafana's open-source project — downloadable and self-hostable for free — has driven extraordinary community adoption: millions of Grafana installations globally power engineering, IoT, and business dashboards at organizations from startups to large enterprises. Grafana's plugin ecosystem connects to 200+ data sources (Prometheus, InfluxDB, Elasticsearch, AWS CloudWatch, databases), making it the universal observability visualization layer. Grafana Cloud packages the open-source tools into a fully managed SaaS offering with unlimited metrics, logs, traces, and dashboards.\n\nIn 2025, Grafana Labs competes in the observability platform market against Datadog, New Relic, Dynatrace, and the ELK/OpenSearch stack for enterprise monitoring and observability. Grafana's open-source-first model creates a moat through developer community and ecosystem — engineers who build personal dashboards on Grafana become advocates for Grafana Cloud at their employers. The company's OpenTelemetry alignment and multi-source data philosophy ("query any data, anywhere") differentiates it from Datadog's monolithic agent model. The 2025 strategy focuses on growing Grafana Cloud enterprise adoption, advancing AI-powered Sift (automatic anomaly investigation), and expanding the Grafana IRM (incident response management) product.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.